Alar Pharmaceuticals Inc. (TPEX:6785)

Alar Pharmaceuticals Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	18.17	382.62	-19.87	-64.23	-142.8
Depreciation & Amortization	3.88	3.35	3.21	3.36	2.84
Loss (Gain) on Equity Investments	8.54	-	-	-	-
Stock-Based Compensation	0.85	-	-	-	0.36
Other Operating Activities	-55.83	-9.65	-15.49	-1.5	-1.62
Change in Accounts Receivable	-	0.84	-0.84	-	-
Change in Accounts Payable	-14.65	18.38	0.31	0.49	-0.15
Change in Unearned Revenue	-	1.25	-	-	-
Change in Other Net Operating Assets	1.38	6.79	-0.26	-1.6	-0.56
Operating Cash Flow	-37.67	403.57	-32.95	-63.47	-141.92
Capital Expenditures	-32.17	-6.34	-1.14	-1.58	-0.39
Investment in Securities	-898.69	-125.66	-30.87	22.67	-
Other Investing Activities	60.5	13.82	2.17	1.42	104.7
Investing Cash Flow	-870.35	-118.18	-29.84	22.51	104.32
Long-Term Debt Repaid	-1.34	-1.28	-0.93	-0.93	-0.89
Net Debt Issued (Repaid)	-1.34	-1.28	-0.93	-0.93	-0.89
Issuance of Common Stock	1,676	-	-	-	550
Common Dividends Paid	-100.2	-	-	-	-
Financing Cash Flow	1,574	-1.28	-0.93	-0.93	549.11
Net Cash Flow	666.37	284.11	-63.71	-41.89	511.5
Free Cash Flow	-69.84	397.23	-34.09	-65.05	-142.31
Free Cash Flow Margin	-1200.58%	84.65%	-4260.75%	-	-23717.83%
Free Cash Flow Per Share	-1.05	6.96	-0.60	-1.14	-2.85
Cash Interest Paid	0.03	0.06	0.02	0.02	0.03
Cash Income Tax Paid	8.41	1.23	0.04	-	-
Levered Free Cash Flow	-92.19	311.67	-28.45	-35.15	-121.22
Unlevered Free Cash Flow	-92.18	311.71	-28.43	-35.13	-121.2
Change in Net Working Capital	22.27	-73.74	1.42	-21.39	17.29

Updated Mar 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.